Minority shareholder opposition to related-party transaction
The proposed scheme to acquire Ster Science injectables business was deferred due to valuation concerns from a long tail of smaller investors, despite majority support.
ONESOURCESPECIALTYPHARMA / bear-case history
Track the concerns that keep returning.
Onesource Specialty Pharma · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Dependence on customer regulatory approvals for revenue ramp
Revenue growth relies on customers obtaining regulatory approvals in various markets; delays could impact sequential improvement.
Capacity ramp-up execution risk
New lines must be qualified and validated on time; any delays could constrain ability to meet robust demand.
Oral semaglutide competition
Oral GLP-1 formulations could capture up to a third of the market, potentially reducing demand for injectable formulations.